888-969-2592
Kalkine 0
countryflagCA

Eupraxia Pharmaceuticals Inc

Healthcare CA EPRX

6.9CAD
0.52(8.15%)

Last update at 2025-06-27T16:31:00Z

Day Range

6.406.90
LowHigh

52 Week Range

3.076.49
LowHigh

Fundamentals

  • Previous Close 6.38
  • Market Cap214.02M
  • Volume55616
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-27.31644M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.91722M -23.36955M -4.01064M -7.24058M -14.83301M
Minority interest 0.66M 0.38M -0.45389M -0.44045M -0.37602M
Net income -23.25937M -22.98961M -3.99720M -7.17614M -13.23198M
Selling general administrative 5.53M 8.41M 1.27M 3.01M 7.54M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.19M 0.11M 0.12M 0.20M 0.13M
Ebit -23.20393M -18.19966M -2.24619M -6.15853M -11.88379M
Ebitda -22.13558M -21.96133M -2.01220M -5.57485M -14.56501M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -23.23561M -20.96741M -2.24619M -6.15853M -14.31472M
Other operating expenses - - - - -
Interest expense 1.59M 1.30M 1.88M 1.46M 0.14M
Tax provision - - - - -
Interest income 0.67M 2.40M 0.00043M 0.01M 0.00111M
Net interest income -1.01904M -1.23096M -1.88121M -1.45174M -0.14107M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 23.20M 18.68M 2.25M 6.16M 14.31M
Cost of revenue - - - - -
Total other income expense net 0.31M -3.46091M 0.12M 0.37M -0.37722M
Discontinued operations - - - - -
Net income from continuing ops -23.91721M -23.36955M -4.01064M -7.24058M -14.83301M
Net income applicable to common shares -23.25937M -22.98961M -3.99720M -7.17614M -13.23198M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 34.94M 26.72M 25.88M 31.22M 1.45M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.36M - - -
Total liab 3.10M 25.55M 13.02M 10.84M 23.12M
Total stockholder equity 33.40M 2.92M 12.86M 20.39M -21.20976M
Deferred long term liab - - - - -
Other current liab - 11.76M - 0.00501M 6.94M
Common stock - 122.52M 92.34M 80.71M 23.80M
Capital stock 148.07M 92.91M 92.34M 80.71M 23.80M
Retained earnings -131.00383M -139.11401M -97.44614M -74.18676M -51.19716M
Other liab - - - - 0.38M
Good will - - - - -
Other assets - 0.00000M 0.00337M 0.03M -
Cash 33.10M 25.50M 24.74M 20.89M 0.15M
Cash and equivalents - - - - -
Total current liabilities 3.10M 25.55M 4.14M 2.27M 22.54M
Current deferred revenue - - - - -
Net debt - -11.72199M - - 12.37M
Short term debt - 13.78M 0.00000M 0.00000M 17.57M
Short long term debt - 10.40M 0.11M 0.09M 12.52M
Short long term debt total - 13.78M - - 0.20M
Other stockholder equity - 23.09M 17.96M 13.86M -
Property plant equipment - - 0.70M 0.59M 0.32M
Total current assets 34.44M 26.11M 25.18M 30.60M 1.14M
Long term investments - - - - -
Net tangible assets - - 12.86M 20.39M -21.20976M
Short term investments - - 0.00000M 9.01M -
Net receivables - 0.25M 0.12M 0.43M 0.62M
Long term debt - - 10.30M 9.26M -
Inventory - 0.00000M - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -3.56886M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00910M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.51M 0.61M 0.70M 0.62M 0.32M
Capital lease obligations 0.07M 0.05M 0.14M 0.20M 0.25M
Long term debt total - - 10.37M 9.40M 0.20M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 9.01M -9.00000M -9.00000M -9.00000M -9.00000M
Change to liabilities 1.78M -0.46748M 0.85M 0.31M 1.35M
Total cashflows from investing activities 8.70M -14.44982M 0.02M -1.89504M -0.14186M
Net borrowings -0.18518M 12.08M -0.39070M 7.40M 3.67M
Total cash from financing activities 13.52M 49.92M -0.62664M 7.40M 5.30M
Change to operating activities -0.02053M 0.07M 0.00291M 0.03M -0.04724M
Net income -23.25937M -22.98961M -3.99720M -7.17614M -13.23198M
Change in cash 3.84M 20.74M -1.00595M 0.33M -3.16668M
Begin period cash flow 20.89M 0.15M 1.16M 0.82M 3.99M
End period cash flow 24.74M 20.89M 0.15M 1.16M 0.82M
Total cash from operating activities -18.77643M -14.64163M -0.40378M -5.17101M -8.32028M
Issuance of capital stock 13.30M 37.83M - - 0.00000M
Depreciation 0.19M 0.11M 0.12M 0.20M 0.13M
Other cashflows from investing activities 9.01M -5.01815M -0.05669M -1.88556M -1.88556M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.31M 0.19M 0.73M 0.14M -0.20858M
Sale purchase of stock 13.71M 37.83M - 0.00000M 1.65M
Other cashflows from financing activities - 0.00000M -0.23595M -0.23595M -0.08719M
Change to netincome 2.22M 8.45M 1.89M 1.32M 3.69M
Capital expenditures 0.31M 0.43M 0.43M 0.00948M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.07M -0.17626M 1.56M 0.48M 1.10M
Stock based compensation 2.02M 4.21M 0.23M 0.54M -
Other non cash items 1.16M 3.41M 1.69M 0.87M 2.08M
Free cash flow -19.08480M -15.07330M -0.40393M -5.18049M -8.46214M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 0.52 8.15% 6.90 - - - 82.33 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -0.11 0.97% 11.22 - 11.95 10.33 57.98 6.90 20.27
TH
Theratechnologies Inc.		 0.10 3.12% 3.30 - 24.75 1.75 19.46 1.79 15.71
MSCL
Satellos Bioscience Inc.		 -0.02 3.28% 0.59 2.40 - - 1.74 6.47
ONC
Oncolytics Biotech Inc		 0.08 8.16% 1.06 - - - 11.76 -2.4457

Reports Covered

Stock Research & News

View All

Profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4

Key Executives

Name Title Year Born
Dr. James A. Helliwell FRCPC, M.D. CEO & Director 1974
Mr. Bruce G. Cousins CPA, C.A., CPA Pres & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Bus. Officer NA
Mr. Bruce G. Cousins C.A., CPA President & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer & COO 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Business Officer NA
Dr. Mark M. Kowalski M.D., Ph.D. Chief Medical Officer 1955
Dr. Rahul Sarugaser M.B.A., Ph.D. Executive Vice President of Corporate Development NA
Mr. Alexander John Rothwell Eng., M.B.A. Chief Financial Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.